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Transforming growth factor a (TGF/3)1 is a 25-kD homo- and heterodimer that
is a multifunctional regulator of cell growth and differentiation (1) . It is present in
awide variety of tissues and interacts with specific cell membrane receptors (2) that
are found on virtually all cells (3) .
A number of functions ofTGFa have been described that suggest a role for it
in tissue repair. Platelets, which are a major storage site forTGF(3 (4), release the
peptide at sites of injury (5). TGF-/3 is a powerful chemoattractant for monocytes,
and stimulates monocytes to increase production of IL-1, which is a potent fibro-
blast mitogen (6). Resting macrophages maintain high steady-state TGFRmRNA
levels and will secrete TGFa upon activation (7) . TGF-0 has also been shown to
bea chemoattractant for fibroblasts (8), andstimulates the growth ofimmature fibro-
blasts (9, 10), suggesting that at sites of injury the presence ofTGFa can recruit
fibroblasts from the surrounding tissues and also stimulate their proliferation and
differentiation . Furthermore, TGF(3 has the combined effect ofenhancing the syn-
thesis of collagen, fibronectin (10, 11), and proteoglycans (12), while suppressing pro-
tease secretion (13, 14) . When injected subcutaneously or applied to incisions, TGF
(3 rapidly stimulates granulation tissue and new blood vessel formation (15, 16) .
Chronicpulmonary fibrosis representsagroup offibrotic lung diseases that result
from a variety of pathological conditions, including chronic infectious and nonin-
fectious inflammation (17) . In the following study, we have used a well-established
rodent model of chronic pulmonary fibrosis induced by a single intratracheal ad-
ministration of the antineoplastic antibiotic, bleomycin (18, 19) . Bleomycin-induced
pulmonary fibrosis resembles the chronic human fibrotic lung disease histologically
and physiologically (19) . The resultant injury is characterized by necrosis of type
I pneumocytes with proliferation of type II pneumocytes (20) . As well, there is evi-
dence of interstitial edema, sequential accumulation of inflammatory cells, fibro-
blasts (21), and finally, collagen and fibronectin synthesis (22-24) .
Because of the well-described effects ofTGFa on inflammatory cells, fibroblasts,
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and connective tissue, we examined the role of TGF-0 in the genesis of chronic pul-
monary fibrosis induced by bleomycin.
Materials and Methods
Animals.
￿
Female Sprague-Dawley rats, which were free of respiratory disease and weighed
between 250 and 300 g, were obtained from the University of Manitoba vivarium. In each
experiment, all rats were matched for age and weight.
Reagents.
￿
Rabbit antiTGF(3 antibodies LC and CC, used for immunohistochemistry, have
been described previously. Both were raised by immunizing with synthetic peptide 1-30 of
the TGF01 (25). LC stains intracellular TGF0 and CC stains extracellular TGF-0associated
with matrix (26). Porcine TGFa1 and neutralizing antiTGF/3 antiserum were obtained from
R & D Systems (Minneapolis, MN). TGF/3, peptide 1-30 and sepharose-linked TGF-0 for
antiserum neutralization have been described previously (27).
Bleomycin Instillation.
￿
Rats were anesthetized by an intraperitoneal injection of40 mg/kg
ofNembutal (Abbott Laboratories, Toronto, Ontario). Tracheostomy was performed and sterile
normal saline containing 1 U of bleomycin sulfate (Blenoxane; Bristol Laboratories, Syra-
cuse, NY) was instilled into the lungs using a 25-gauge needle inserted between cartilagenous
rings of the trachea. The tracheal site of surgery was sutured and the rats were allowed to
recover until the time of lung harvesting.
At appropriate time intervals, the rats were killed by cervical dislocation. Lungs to be used
for TGF(3 extraction were removed and flushed through the right ventricle with heparinzed
(5 U/ml) PBS. The lungs were then frozen in liquid nitrogen and stored at -70°C.
Immunohistochemical Staining.
￿
TGF/3 was localized in sections of lungs of rats treated with
intratracheal bleomycin at a number of time intervals. Lungs were exposed through a mid-
thoracotomy incision and were filled with 10% neutral buffered formalin injected through
the trachea. The trachea was then tied and the lungs were immersed in the buffered formalin
for 24 h. The lungs were then transferred to Bouin's solution (0.9% picric acid, 9% (vol/vol)
formaldehyde, 5% acetic acid) for 4-6 h at room temperature and then rinsed with 70%
ethanol. They were stored in 70% ethanol until ready for embedding in paraffin.
The immunohistochemical stainingprocedure has been described previously (28). Briefly,
the sections were incubated overnight at 4°C with 15-20 lzg/ml ofpretitred antiTGFQ IgG.
After extensive washing, the sections were blocked with normal goat serum, then incubated
with affinity-purified goat anti-rabbit IgG and avidin-enzyme-complex (Vector Laborato-
ries, Inc., Burlingame, CA). Staining was visualized by incubating with alkaline phosphatase
red (Vector Laboratories, Inc.), as per manufacturer's instructions, and counterstained with
1 % methyl green for 1 min. Controls consisted of replacing anti TGF0 by normal rabbit
IgG and using antisera depleted by incubation with TGF0 sepharose resin (27). In blocking
experiments, TGF-0peptide 1-30 was added to sections before TGFS antibody, as described
previously (26).
7GF--,B Extraction Procedure.
￿
To previously frozen lungs, 4 ml of an acid-ethanol solution
(957o ethanol, 0.2 M HCl) containing 1 ttg/ml each ofPMSF (Sigma Chemical Co., St. Louis,
MO) and pepstatin (United States Biochemical Corp., Cleveland, OH) was added as described
(27). The lungs were then homogenized using a Polytron tissue homogenizer (Brinkmann
Instruments Co., Westbury, NY). The homogenate was stirred overnight at 4°C and cen-
trifuged at 10,000 g for 10 min. The supernatant was diluted with two parts distilled water
and lyophylized. It was then resuspended in 2 ml of 4 mM HCl with 0.1% BSA per lung,
centrifuged to remove insoluble particles, then stored at -80°C until assayed. Samples were
neutralized with 2-3 g,l of 5 N NaOH and 1 M Hepes before use, and any precipitate was
removed by a 5-min centrifugation at 10,000 rpm on a microfuge (Beckman Instruments,
Inc., Palo Alto, CA).
Lung Fibroblast Isolation.
￿
Bleomycin-treated rats were killed at different time intervals by
cervical dislocation and the lungs with the heart were removed under sterile conditions and
placed in cold PBS and heparin (5 U/ml). After flushing lungs through the right ventricle
with heparinized PBS, the heart and major bronchi were removed. The lungs were manually
minced with fine scissors and digested in 0.04% trypsin EI7TA (Gibco Laboratories, GrandKHALIL ET AL.
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Island, NY) and 0.1% collagenase I (Sigma Chemical Co.) for 20 min at 37°C in 5% C02.
After rigorous vortexing, the trypsin was inactivated by addition of F12 medium (Gibco Labora-
tories) with 20% FCS (Gibco Laboratories). The digest was passed through sterile nylon mesh,
centrifuged, and the cell pellet was retained. RBC in the pellet were removed by hypotonic
lysis and the remaining cells were resuspended as 105 cells/ml in a-MEM with 5% fetal bo-
vine plasma (FBP) with gentamycin (40 ug/ml) (Schering, Pointe Claire, Quebec) and Fungi-
zone (0.25 pg/ml) (Gibco Laboratories). FBP was used because it contained very low levels
of TGF-0 compared with serum and did not interfere with measurements of collagen syn-
thesis. It also enhanced fibroblast adhesion to the microwells. The cells were seeded as 105
cells/well in triplicate in a 24-well tissue culture plate and incubated for 16-20 h at 37 °C
in 5% C02.
AssayforCollagen SynthesisIn Vitro.
￿
After 24 h in culture, lung fibroblasts were assayed for col-
lagen synthesis as described by Roberts et al. (15). Briefly, cells were washed with a-MEM
to remove nonadherent cells. To each well, 300 Al of 1017o (FCS) MEM with ascorbate (0.25
mM), Hepes (20 mM), and NaHC03 (350 mg/liter) was added. Then, 25 Al of L-[2,3-3H]
proline (29-1 A/mmol; 1 Ci, 37 GBq) (Amersham International, Amersham, UK) was added
and the cells were incubated for 3 h at 37oC. Media were pooled from the triplicates and
the unicorporated radioactive amino acids were separated from the proteins by 5% TCA
(Fisher Scientific Co., Pittsburg, PA) precipitation. The TCA-precipitated protein was redis-
solved in 0.2 M NaOH. Equal portions (150 Al) were neutralized with 0.7 N HCl and 1 M
Hepes and incubated with or without collagenase III (Advanced Biofactures, Lynbrook, NY)
at 37oC for 90 min. The proteins were reprecipitated with 40% TCA and 1% tannic acid
(Sigma Chemical Co.) After centrifugation the supernatant containing peptides derived from
collagen was removed into a counting vial. The pellet containing the noncollagen protein
was dissolved in 200 Al of 80% formic acid and placed in the protein fraction vial. Then,
10 ml of Scintiverse II (Fisher Scientific Co.) was added and all vials were counted in a /3
Scintillation Counter (Beckman Instruments, Inc.). The remaining cells were used to calcu-
late micrograms of DNA by the method of Burton. The data were calculated as described
by Roberts et al. (15) and presented as dpm/min/pg DNA.
CCL-64 Mink Lung Growth Inhibition Assayfor 7UF--,6.
￿
CCL-64 mink lung epithelialcells
were maintained in DME (Gibco Laboratories) with 10% FBP Subconfluent cells were used
in the TGF/3 growth inhibition assay as described by Danielpouret al. (27). Cells were tryp-
sinized and washed with a-MEM in 0.2% FBP, and resuspended in DME, 0 .2% FBP, 10
mM Hepes at pH 7.4, penicillin (25 U/ml), and streptomycin (25 hg/ml), and seeded as 5 x
105 cells per 0.5 ml in 24-well Costar dishes (Flow Laboratories, Inc., Missisauga, Ontario).
Aliquots of neutralized acid ethanol-extracted lung preparations with and without TGF/3
antibody (R & D Systems) were added 3 h later. Antibody was always placed in the wells
before lung samples. After 22 h, the cells were pulsed with 0.25 ACi (5 Ci/mg) of 5'-[1251]iodo
2'-deoxyuridine for 2-3 h at 37oC. Cells were then fixed with 1 ml of methanol-acetic acid
(3 :1) (vol/vol). After 1 h at room temperature the wells were washed twice with 2 ml of 80%
methanol. The cells were lysed with 1 ml of 1 N NaCH for 30 min at room temperature
and the 1251-UdR was counted in an gamma counter (LKB Instruments, Inc., Gaithersburg,
MD). A standard curve ofporcine TGF0 was included in each assay and data were expressed
as micrograms of TGF(3, as described (27).
Results
To determine whether TGFa might be involved in the genesis ofpulmonary fibrosis
after bleomycin injury, we initially examined the total TGFS content of rat lungs
at increasingtime intervals after instillation ofbleomycin into the trachea of Sprague-
Dawley rats. After acid-ethanol extraction of lungs, lyophilization, and reconstitu-
tion, as described in Materials and Methods, we measured TGFa levels using the
CCL-64 mink epithelial lung cell inhibition assay (27). By assaying inhibition in
the presence or absence of polyclonal rabbit antiTGFS antiserum, which blocks
both TGF01 and -(32, we were able to estimate the total TGFfl content of the lung.730 TRANSFORMING GROWTH FACTOR 0 IN PULMONARY INFLAMMATION
Fig. 1 presents the TGF(3 levels per lung at different time points after bleomycin
administration. Detectable levels were foundwithin 2 h, with a progressive but slow
increase to about day 4. A 30-fold increase was seen at day 7, which was the peak
response, followed by a gradual decrease over the followingweeks. TGF0 levels re-
mained significantlyelevated abovecontrollevels forthe full 28 d ofthe experiment.
If TGF(3 was a major contributor to the induction of pulmonary fibrosis, then
one would expect it to either precede or be coincidental with the synthesis of col-
lagen by pulmonary fibroblasts. We have assayed collagen synthesis by measuring
collagenase-sensitive [3H]proline incorporation in fibroblasts isolated from
bleomycin-treated lungs at the same time intervals at which weassayedTGF/3 levels.
By evaluating isolated lung fibroblasts within 24 h of recovery from the lung, we
were able to identifyenhanced collagen synthesisinthebleomycin-treated ratlungs.
The methodology also allowed us to compare the relative synthesis ofcollagen and
noncollagen protein per microgram DNA, which is presented in Fig. 2. Collagen
synthesis increased gradually and was minimally butdetectably above untreated con-
trols 7 d after bleomycin administration. It reachedapeak ofsynthesisby 14d, which
was past the point at which TGF0 content oflungs was at its maximum. Collagen
synthesis decreased but remained signficantly above untreated controls for the full
28 d ofthe assay, paralleling the TGF-(3 content ofthe lungs. Changes in the level
of[3H]proline incorporation into noncollagenous protein followed the identical pat-
tern with that of collagen .
To determine the source ofTGF0 production during thecourse ofthe bleomycin-
induced lung injury, we examined lungsat all time points by immunohistochemical
staining. The two antibodies used for this procedure have been described (26, 28)
and are ableto distinguish between intracellularTGF0(LC), andextracellularTGF0
(CC) that is associated with stromal tissue or matrix. To confirm that all staining
was specific, each experimentand eachtime point wascontrolledusingthe IgGfrac-
tion from normal rabbit serum. Furthermore, examples ofpositively stained tissue
were re-examined with antiTGF(3 antibodies after preabsorption with insolubilized
TGF0, or blocked with specific peptides corresponding to the NH2-terminal amino
acids 1-30 ofTGF(3, which were used as antigens for the generation ofthese poly-
clonal antibodies (27). The fixation procedure described in the methodology, using
a
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FIGURE 1.
￿
Total extractable TGF-0 per
rat lung at increasing time intervalsafter
intratrachealadministration ofbleomycin.
Lungs were acid-ethanol extracted, lyophi-
lized, then resuspended andassayed in the
CCL-64 lung epithelial cell growth inhi-
bition assay (27). Each point (0) repre-
sents twoto threelungs. The ED5o growth
inhibition was converted to TGFS levels
on the basisof aporcine TGF01 standard
curve. Each extract was also treated with
antiTGF0 antiserum(0)to confirm the
growth inhibition was due to TGF-,6.first neutral formalin, the Bouin's solution, was critical for thedetection of theTGF
(3 staining outlined below (28).
Within 2 h of bleomycin instillation in the trachea, intracellular staining with LC
antibody wasdetected in bronchiolarepithelium (Fig. 3A). Stainingin thesubepithelial
matrix was seen at the same time and up to 4 d later with the CC TGF/3 antibody
(Fig. 3 B). Although some staining with these antibodies wasseen in normal animals,
the extent and intensity were much increased in the bleomycin-treated group. Rare
macrophages stained with the LC antibody were also detected in normal animals.
By 4 d after bleomycininstallation, increasing numbers ofmacrophages that stained
intensely with the LC TGF(3 antibody were seen associated with areas ofincreased
cellularity in the alveolar walls. The distribution was still patchy and little macro-
phage organization was observed until 7 d. At this time point, there was widespread
evidence of collagen staining with Masson's trichrome (data not shown) and wide-
spread intense staining of macrophages (Fig. 3 C), which was the most pronounced
throughout the entire time course, and coincided with the peak levels of TGFO in
the lung (Fig. 1). Besidesobserving TGFO containing macrophages as isolated cells,
areas ofhighly organized but less intensely stained macrophages were now evident
(Fig. 3 D). By 14 d the isolated intensely staining macrophages had disappeared,
and only the organized macrophages remained. At this time, TGF-0 levels in the
lung were decreasing. As early as 7 d, and clearlyby 14 d, a second pattern of staining
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FIGURE 2. [3H]Proline incorporation
into collagen and noncollagen protein of
lung fibroblasts recovered from bleomycin-
treatedanimals. At sequential time points
(") afterintratracheal bleomycin instilla-
tion, progressively increasing [3H]proline
incorporation into both collagen (upper
panel) andnoncollagen protein(lowerpanel)
wasobserved. Peak [3H]proline incorpo-
ration occurred at 14 d after bleomycin.
Collagen synthesisdecreasedafter 14 dbut
remained above baseline to 28 d. The
proportion of [3H]proline incorporated
into collagen remained two- to threefold
higher than background (middle panel).
Total collagen synthesis in rats 14 dafter
intratracheal injectionwith saline (O)in-
steadof bleomycin wasnot different from
untreated controls (upper panel). The
number of animals in each groupis indi-
cated in brackets in the upper panel.73 2 TRANSFORMING GROWTH FACTOR S IN PULMONARY INFLAMMATION
FIGURE 3 .
￿
Immunolocalization of TGF-/3 in rat lung after intratracheal bleomycin induction
of chronic pulmonary inflammation . (AJ) Antibody to TGF-0 I NH2-terminal synthetic pep-
tide (anti-LC-[1-301) localizes in the cytoplasm ofbronchiolar epithelium (arrows) . Avidin-biotin-
alkaline phosphatase (red) detection system was used with methyl green counter stain (bar, 50
p.M) . (A.2) TGF-0 staining was blocked by preabsorption with sepharose on which TGF-/3 had
been coupled . (B) Anti-CC (1-30) antibody to TGF-/3I localizes to subendothelium primarily
staining connective tissue 1 d after bleomycin administration (arrows) (bar, 50,M). (C)Anti-LC
(1-30) localizes to macrophages 7 d after bleomycin . The cytoplasm of the macrophages is in-
tensely positive (arrows) . Staining wasblocked or greatly diminished by preincubation with 20-
fold molar excess of peptide LC (1-30) (not shown) (bar, 50 FAM) . (D)Anti-LC (1-30) antibody
localizes to macrophages organized in clusters between 7 and 14 d after bleomycin (arrow) (bar,Bmnchid
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FIGURE 4.
￿
Summaryofthe distribu-
tion and intensityof TGF0 immuno-
histochernical staining in lungs after
bleomycin administration.
was evident withtheCC antibodies. This antibody detected intense TGF/3 staining
associated with areas ofrepair with hypercellularity and collagen deposition (Fig.
3, E and F). The staining was associated with matrix and occurred at the edges of
theseintensely hypercellular areas. This pattern ofstaining, a combinationofweakly
staining organized macrophages, and areas ofmatrix-associated TGF(3 staining in
focal regions ofhypercellularity, persisted throughtoday 28. Throughout this period,
TGF/3 levels in the lung were above background, and significant collagen synthesis
was detected in isolated lung fibroblasts. The pattern ofstaining in all lung tissues
over the 28 d of the experiment is summarized in Fig. 4.
Discussion
The histological andphysiologicalchanges associated with bleomycin-induced pul-
monary fibrosis (BPF) have been extensively studied andreported(18-24). Although
manylymphokineshave been implicated inthe inflammatory andfibroblast prolifer-
ative response consequent to bleomycin-induced pulmonary injury, the regulation
offibrosis and repair remains unresolved. Recently, Hoyt and Lazo (24) found that
early after bleomycin infusion they detected an elevation ofTGF0 mRNA in lungs
ofbleomycin-susceptible but not bleomycin-resistant mice. These changespreceded
increases in pulmonary fibronectin, procollagen 012(1) and 01I(III) mRNA content
and suggested that TGF, may participate in therepair response. TheTGF0 mRNA
increase could have resulted from either altered synthesis/degradation, or simply
from changes in pulmonary cell content. For example, TGF-0 steady-state mRNA
levels arehigh in normal macrophages, and translation does not occuruntil the cells
are activated (7), consequently, entry ofnonTGF0-secretingmacrophages into the
lung would alter mRNA content. Itwas, therefore, unclear from this study whether
TGF-/3 was being actively produced. It was the purpose of our study to examine
theproductionofTGF(3, identify its source, andcorrelate it withlung collagen syn-
thesis. We have observed arapid and substantial increase in TGF0 production that
was temporally related to enhanced synthesis of collagen and noncollagen protein
in pulmonary fibroblasts. Furthermore, TGF0 was identified in three tissue sites:
(a) macrophages, whether isolated or organized in clusters; (b) bronchiolar epithe-
100pM). Inset(top)showsahigher powermagnification oforganizedstained macrophages adja-
cent to areas ofhypercellularity (arrow)(bar, 50 I4M). Inset(bottom) showsabsenceofmacrophage
staining (arrow)using normal rabbit IgG in placeof LC antibody. (E) Anti-CC (1-30) antibody
intensely staining localized areas at the edge of regions of hypercellularity 14 d afterbleomycin
(arrows) (bar, 100gm). (F)High powerof E illustrating staining primarily in interstitial connec-
tive tissue in whorl patterns (arrows). Staining was blocked or greatly reducedby preabsorption
of antiserum on sepharose-linked TGFS (not shown) (bar, 50 IAM).734 TRANSFORMING GROWTH FACTOR /3 IN PULMONARY INFLAMMATION
lium and subepithelial matrix; and (c) extracellular matrix associated with areas of
repair and collagen synthesis.
The initial TGF(3 response to bleomycin is localized to the bronchiolar epithelial
cellsand subepithelialmatrix. Since littleTGF-/3 was seen in the bronchiolar epithe-
lium of untreated animals, and minimal amounts were extracted from untreated
animals, it suggests that this is aresponsetothe bleomycin-induced injury. Thesource
ofTGF-(3 in subepithelial matrix is likely from the bronchiolar epithelial cells them-
selves, or possibly from platelets that have degranulated in response to bleomycin
vasular injury. TGF(3 is a chemoattractant to monocytes and macrophages (6), and
the early TGF0 production by bronchiolar epithelial cells may represent a mecha-
nism for recruiting macrophages into the damaged area.
Once in damaged tissue, and activated, macrophages have been shown to secrete
TGF-/3 (7). This is the first report that macrophages recruited to an area of lung
injury are producers of TGF-/3. Since the intense intracellular TGF0 staining in
alveolarmacrophages afterbleomycin coincides with the peak extractable totallung
TGF0 activity (Fig. 1) and total TGF(3 mRNA (24), this suggests that the main
source of TGF-/3 in bleomycin-damaged lungs is from pulmonary macrophages.
By 14 d after bleomycin instillation, [3H]proline incorporation into collagenous
protein was at its peak . This point of maximal collagen production in our study
corresponded to the rise in mRNA of procollagen az(I) and at(III) reported by
others (22, 23). The biochemical and immunohistochemicalevidence ofTGF(3produc-
tionprecedingcollagen synthesis anddeposition suggeststhatTGF(3maybe regulating
collagen production in BPF. Although we have shown elevation ofextractable lung
TGF0, and described itspresence in macrophages, we have provided no direct evi-
dence of its secretion. However, the changing pattern of TGF0 distribution from
initial intracellular stainingin macrophages to association with extracellular matrix
(Fig. 4) suggests it is being actively secreted and deposited onmatrix. Furthermore,
the most intense matrix staining occurs at the peak ofcollagen synthesis. Therefore,
it is possiblethat once TGF0has become associated with extracellular matrix, it re-
mains localized, recruiting fibroblasts to the siteand subsequently inducing themto
produce collagen. It is ofinterest that histological studies oflung sections show that
whencollagen is detectable by Massons Trichrome stain it is often in alocalizedwhorl-
like or nodular pattern. This suggests that collagen is laid down in a similar pattern
ofdistribution to TGF0 (see Fig. 3, E andF). This speculation is supported by the
observation that granulation formation and increased collagen synthesis occur at
sites ofTGF/3instillation into subcutaneous tissue (15) orwhen applied towounds (16).
Although diminished in amount, extractable TGF/3 levels and collagen synthesis
persist chronically up to 28 d after bleomycin instillation. Immunohistochemical
staining suggests that much ofthe TGF0 in the chronic phase ofinjury is extracel-
lular in distribution, although areas of organized weakly stained macrophages do
remain. The persistently elevated amounts ofextractable TGF0 in the later phase
maybederivedboth from previously synthesized, secreted, and extracellular matrix-
associated TGF(3, aswellas from macrophages. This continued associationofTGF(
production and collagen synthesis supports the hypothesis that chronic fibrosis is
mediated byTGF/3. Furthermore, this would suggest that in diseases characterized
by chronic pulmonary fibrosis, such as active idiopathic pulmonary fibrosis, sar-KHALIL ET AL.
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coidosis, or Hamman-Rich syndrome, in which acontinuous inflammatory response
is evident, TGF-0 production may be etiologic.
In conclusion, we have presented evidence that TGF(3, a peptidewell recognized
for its effects on inflammatory cells, fibroblasts, and collagen production, is pro-
duced in 30-fold elevated levels during the course of BPF and is found primarily
in pulmonary alveolar macrophages. The increase in macrophage TGFO produc-
tion precedes collagen synthesis while the peak of collagen production coincideswith
thepresence of extracellularTGF0. This temporal relationship and histological dis-
tribution suggest a role for the aberrant production of TGF(3 in the pathogenesis
of pulmonary fibrosis .
Summary
Aratmodelofbleomycin-induced pulmonaryinflammation and fibrosis wasused
to examine the relationship between collagen synthesis and transforming growth
factora(TGF(3)production, and cellular distribution. Totallung TGF(3 waselevated
within 2 h of intratracheal bleomycin administration and peaked 7 d later at levels
30-fold higher than controls. This was followed by a gradual decline with lower but
persistent levels of production in the late phase of the response between 21 and 28
d later. The peak TGFa levels preceded the maximum collagen and noncollagen
protein synthesis measured by [3H]proline incorporation into lung fibroblast ex-
plants of bleomycin-treated rats. The pattern of immunohistochemical staining local-
ized TGF-0 initially in the cytoplasm ofbronchiolarepithelium cells and subepithelial
extracellular matrix. The peak of lung TGFO levels at 7 d coincided with intense
TGF-0 staining of macrophages dispersed in the alveolar interstitium and in orga-
nized clusters. Later in the course of the response, TGF-0 was primarily associated
with extracellular matrix in regions of increased cellularity and tissue repair, and
coincided with the maximum fibroblast collagen synthesis. This temporal and spa-
tial relationship between collagen production andTGF-0 production by macrophages
suggests an important if not primary role for TGF(3 in the pathogenesis ofthe pul-
monary fibrosis.
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